AMY DEMONBREUN: Open Payments
NPI 1548801954 · VENICE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$681 in 31 payments from 12 companies in 2025. Trend: 2023 $764 · 2024 $820 · 2025 $681
Food & beverage: $572Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $168 |
| Eli Lilly and Company | 1 | $99 |
| Amgen Inc. | 3 | $73 |
| GENZYME CORPORATION | 2 | $55 |
| Galderma Laboratories, L.P. | 3 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $51 |
| STRATA Skin Sciences, Inc. | 4 | $48 |
| Lilly USA, LLC | 2 | $44 |
| MERZ NORTH AMERICA, INC. | 1 | $29 |
| Janssen Biotech, Inc. | 1 | $24 |
Products named: SKYRIZI, OTEZLA, DUPIXENT, XTRAC, TALTZ, NEMLUVIO, Xeomin, COSENTYX.
Industry payments across FL — which companies pay providers there.
